DOCSLIB.ORG

Report on Cardiovascular Diseases in China 2018 中国心血管病报告 2018

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Report on Cardiovascular Diseases in China 2018 中国心血管病报告 2018 REPORT ON CARDIOVASCULAR DISEASES IN CHINA 2018 中国心血管病报告 2018 National Center for Cardiovascular Diseases, China 国家心血管病中心 Encyclopedia of China Publishing House 图书在版编目 (CIP)数据 中国心血管病报告. 2018：英文 / 国家心血管病中 心编著. -- 北京 ：中国大百科全书出版社，2019.11 ISBN 978-7-5202-0632-7 Ⅰ.①中… Ⅱ.①国… Ⅲ. ①心脏血管疾病－研究报 告－中国－2018－英文 Ⅳ .①R54 中国版本图书馆CIP数据核字 (2019)第256560号 责任编辑：杨 振 出版发行 (北京阜成门北大街17号 邮政编码：100037 电话：010-88390752) http://www.ecph.com.cn 北京骏驰印刷有限公司印刷 (北京市海淀区西北旺屯佃工业园区289号) 新华书店经销 开本：889×1194毫米 1/16 印张：15 字数:300千字 2019年12月第一次印刷 印数：1－3000册 ISBN 978-7-5202-0632-7 定价:128.00元 本书如有印装质量问题，可与本出版社联系调换。 ISBN 978-7-5202-0632-7 Copyright by Encyclopedia of China Publishing House,Beijing,China,2019.11 Published by Encyclopedia of China Publishing House 17 Fuchengmen Beidajie,Beijing,China 100037 http://www.ecph,com.cn Distributed by Xinhua Bookstore First Edition 2019.12 Printed in the People´s Republic of China EDITORIAL COMMITTEE for Report on Cardiovascular Diseases in China (2018) Chief Editor Hu Shengshou Associate Editors Gao Runlin; Wang Zheng; Liu Lisheng; Zhu Manlu; Wang Wen;Wang Yongjun; Wu Zhaosu; Li Huijun; Gu Dongfeng;Yang Yuejin; Zheng Zhe; Chen Weiwei Academic Secretaries Ma Liyuan; Wu Yazhe Writing Group Members Chen Weiwei; Du Wanliang; Fan Xiaohan; Li Guangwei; Li Jing; Li lin; Li Xiaoying; Liu Jing; Liu Kejun; Luo Xinjin; Ma Liyuan; Mi Jie; Wang Jinwen; Wang Wei; Wang Yu; Wang Zengwu; Wu Yazhe; Xiong Changming; Xu Zhangrong; Yang Jingang; Yang Xiaohui; Zeng Zhechun; Zhang Jian; Zhang Shu; Zhao Liancheng; Zhu Jun; Zuo Huijuan Editorial Board Members Chang Jile; Chen Weiwei; Chen Yude; Du Wanliang; Gao Runlin; Gu Dongfeng; He Jianguo; Hu Shengshou; Kong Lingzhi; Li Guangwei; Li Huijun; Li Wei; Li Xiaoying; Liu Jing; Liu Kejun; Liu Lisheng; Luo Xinjin; Mi Jie; Rao Keqin; Tang Xinhua; Wang Wei; Wang Wenzhi; Wang Yilong; Wang Yongjun; Wang Yu; Wang Zengwu; Wang Zheng; Wu Liangyou; Wu Xigui; Wu Zhaosu; Xu Zhangrong; Yang Gonghuan; Yang Xiaohui; Yang Yuejin; Yao Chonghua; Zeng Zhechun; Zeng Zhengpei; Zhang Jian; Zhang Shu; Zhao Dong; Zhao Liancheng; Zhao Wenhua; Zheng Zhe; Zhu Jun; Zhu Manlu; Zuo Huijuan Academic Committee Members Cao Kejiang; Cao Xuetao; Chen Haozhu; Chen Hong; Chen Jiyan; Chen Keji; Chen Lianglong; Chen Lin; Chen Weiwei; Chen Xiangmei; Chen Yundai; Chen Zaijia; Cheng Xiansheng; Dong Yugang; Du Jie; Fang Quan; Gao Changqing; Gao Chuanyu; Gao Wei; Gesang Luobu; Ge Junbo; Gu Dongfeng; Guo Tao; Han Yaling; Hu Dayi; Hu Shengshou; Huang Congxin; Huang Dejia; Huang Lan; Hui Rutai; Huo Yong; Jia Shaobin; Jiang Shiliang; Kong Xiangqing; Lei Han; Li Fen; Li Guangwei; Li Guangping; Li Huijun; Li Jianjun; Li Lihuan; Li Liming; Li Ling; Li Wei; Li Xiaoying; Li Yong; Liao Yuhua; Lin Shuguang; Liu Bin; Liu Depei; Liu Jin; Liu Lisheng; Liu Weijun; Liu Xiaocheng; Liu Yuqing; Long Cun; Ma Changsheng; Ma Yitong; Pan Changyu; Shen Weifeng; Shi Dazhuo; Sun Ningling; Sun Yingxian; Tang Baopeng; Tang Chaoshu; Wan Zheng; Wang Daowen; Wang Chen; Wang Chunsheng; Wang Fangzheng; Wang Jiguang; Wang Jian' an; Wang Jingfeng; Wang Shiqiang; Wang Wei; Wang Xian; Wang Yongjun; Wang Zengwu; Wang Zheng; Wu Liqun; Wu Ming; Wu Yiling; Wu Zhaosu; Wu Zonggui; Wu Weifeng; Xiao Chuanshi; Xiao Ruiping; Xu Bo; Xu Zhangrong; Yan Ji; Yan Xiaowei; Yang Baofeng; Yang Jiefu; Yang Tianhe; Yang Xinchun; Yang Yuejin; Yao Chonghua; Yi Dinghua; Yu Bo; Yuan Zuyi; Zeng Zhengpei; Zhang Shuyang; Zhang Shu; Zhang Yun; Zhang Zheng; Zhao Dong; Zhao Shuiping; Zhao Xingsheng; Zheng Yang; Zheng Zhe; Zhou Shenghua; Zhu Jianhua; Zhu Xiaodong; Zhu Junren; Zhu Zhiming; Zhuang Jian Translators China Oxford Center for International Health Research, Fuwai Hospital, China: Ge Yilan; Huo Xiqian; Lu Jiapeng; Su Meng; Wu Chaoqun; Wang Xiuling; Yi Jiayi; Yu Yuan; Zhang Danwei; Zhang Lihua; Zhang Qiuli; Zhang Xingzi Yale University, US Luo Jiesi University of Missouri, US Shen Yuanyuan Adivo Associates LLC Zhu Xianglong Oxford University Usama Ali Text Proofreaders National Center for Cardiovascular Diseases, Fuwai Hospital, China: Ma Liyuan Department of Geriatric Cardiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University Zhao Yong Preface Rapid socioeconomic progress in China has greatly impacted the lifestyle of citizens. The tendency to develop cardiovascular diseases (CVD) has increased in China as a consequence of lifestyle changes, urbanization, and the accelerated aging of the population. The incidence of CVD has been continuously increasing and will continue an upward trend in the next decade. CVD is the leading cause of death in both urban and rural Chinese populations. Currently, 45.50% of deaths in rural areas and 43.16% in urban areas are attributable to CVD. The growing burden of CVD has become a major public health issue. Effective strategies for the prevention and treatment of CVD should be enforced urgently under the supervision of the government. On 14th February 2017, General Offi ce of the State Council issued The Medium- and Long-term Plan for Chronic Disease Prevention and Control in China (2017-2025), a guideline for the prevention and control of chronic diseases, especially CVD in China, which should be appropriately followed and implemented as the recommendations. Since 2005, the National Center for Cardiovascular Diseases has been recruiting experts nationwide to compile the Report on Cardiovascular Diseases in China annually (herein after referred to as the annual report). To date, 13 annual reports have been published. In the year of the publication of the fi rst annual report, it was selected among the top ten academic news for its innovation and importance. In 2015, the National Health Commission listed the annual report as one of the fi ve most important regularly- released health information in the fi eld of diseases prevention and control in China. The annual report was published to dynamically track the prevalence of CVD and comprehensively evaluate the progress of research on CVD prevention in the country. It covers various aspects of the research and development of prevention for CVD throughout the nation, primarily focusing on monitoring cardiovascular (CV) epidemic trends to guide the management of CVD. The report seeks to be comprehensive, timely, accurate and complete, to refl ect its representativeness and authority, and to provide technical guidance for the government, medical research institutions and communities to carry out more effective research on prevention and control of CVD. In addition to maintaining the continuity of the core content in the previous annual reports, the Report on Cardiovascular Diseases in China 2018 has added three key points to deal with the current severe situation of CVD in China: (1) Prediction for the trend of CVD and individual risks in Chinese population. A comprehensive analysis of predictive models on CVD risks was performed in individuals or populations at different control levels of risk factors, emphasizing a lifetime risk assessment for young- and middle- aged people with low- or intermediate-level of risk of CVD, to facilitate the early prevention and control of CVD; (2) Medical care quality assessment on CVD. Based on relevant literatures published in recent years, objective analysis was conducted on the medical care quality of CVD in China. It revealed that both progress and weakness exist. In 2015, the medical care quality and accessibility index in China 1 Report on Cardiovascular Diseases in China 2018 ranked the 48th in the world, and the progress ranked third between 1990 to 2015. The medical care quality of CVD in China is improving steadily. The proportion of implementing standardized medications and other treatments recommended by the guidelines is increasing, but there is still much room for improvement. Moreover, the disparity of medical care capabilities in different hospitals at different levels is still signifi cant. (3) At the end of the annual report 2018, we added the appendix of Guidelines for CVD Released in China in the Past Five Years , listing the titles, institutions, and the published journal names for reference. It should be noted that the term “cardiovascular diseases” in this report refers to cardiovascular and cerebrovascular diseases, as well as their related diseases. The information in the annual report is an essential reference for the government to formulate relevant policies. It serves as an information platform for national prevention and control of CVD, and for international communication and cooperation. It is also a crucial element of enhancing China's international status and infl uence in the research fi eld of CVD management. The work of compiling the Report on Cardiovascular Diseases in China has received full support from the leaders of the National Health Commission, the National Center for Cardiovascular Diseases, the Fuwai Hospital, the annual report writing group members, the editorial board, and the academic committee, especially the experts from the writing group. We would like to express our deep appreciation to them. Although we strive for excellence in the process of writing, there might still be some missing information. We look forward to having valuable opinions from the readers to make the annual report better. 2 Abbreviations and Acronyms ABI：Ankle Brachial Index CI：Confi dence Interval ACC：American College of Cardiology CIMIC：Community Intervention of Metabolic ACEI：Angiotensin Converting Enzyme Inhibitor Syndrome in China ACR：(Urinary) Albumin/Creatinine Ratio CKB：China Kadoorie Biobank ACS：Acute Coronary Syndrome CKD：Chronic Kidney Disease
Load more

Recommended publications
  • Program PDF Saturday, March 28, 2020 Updated: 02-14-20
    Program PDF Saturday, March 28, 2020 Updated: 02-14-20 Special ‐ Events and Meetings Congenital Heart Disease ‐ Scientific Session #5002 Session #602 Fellowship Administrators in Cardiovascular Education and ACHD Cases That Stumped Me Training Meeting, Day 2 Saturday, March 28, 2020, 8:00 a.m. ‐ 9:30 a.m. Saturday, March 28, 2020, 7:30 a.m. ‐ 5:30 p.m. Room S105b Marriott Marquis Chicago, Great Lakes Ballroom A CME Hours: 1.5 / CNE Hours: CME Hours: / CNE Hours: Co‐Chair: C. Huie Lin 7:30 a.m. Co‐Chair: Karen K. Stout Fellowship Administrators in Cardiovascular Education and Training Meeting, Day 2 8:00 a.m. LTGA, Severe AV Valve Regurgitation, Moderately Reduced EF, And Atrial Acute and Stable Ischemic Heart Disease ‐ Scientific Arrhythmia Session #601 Elizabeth Grier Treating Patients With STEMI: What They Didn't Teach You in Dallas, TX Fellowship! Saturday, March 28, 2020, 8:00 a.m. ‐ 9:30 a.m. 8:05 a.m. Room S505a ARS Questions (Pre‐Panel Discussion) CME Hours: 1.5 / CNE Hours: Elizabeth Grier Dallas, TX Co‐Chair: Frederick G. Kushner Co‐Chair: Alexandra J. Lansky 8:07 a.m. Panelist: Alvaro Avezum Panel Discussion: LTGA With AVVR And Reduced EF Panelist: William W. O'Neill Panelist: Jennifer Tremmel Panelist: Jonathan Nathan Menachem Panelist: Joseph A. Dearani 8:00 a.m. Panelist: Michelle Gurvitz Case of a Young Women With STEMI Panelist: David Bradley Jasjit Bhinder Valhalla, NY 8:27 a.m. ARS Questions (Post‐Panel Discussion) 8:05 a.m. Elizabeth Grier Young Women With STEMI: Something Doesn't Make Sense...
    [Show full text]
  • 2019 World Championships Statistics – Men’S HJ by K Ken Nakamura
    2019 World Championships Statistics – Men’s HJ by K Ken Nakamura The records to look for in Doha: 1) Can Starc become first AUS to win the World Championships? 2) Can Barshim become only the second HJ (after Sotomayor) to win back to back WC? Summary: All time Performance List at the World Championships Performance Performer Height Name Nat Pos Venue Year 1 1 2.41 Bohdan Bondarenko UKR 1 Moskva 2013 2 2 2.40 Javier Sotomayor CUB 1 Stuttgart 1993 3 3 2.38 Patrik Sjöberg SWE 1 Roma 1987 3 3 2.38 Igor Paklin URS 2= Roma 1987 3 3 2.38 Gennadiy Avdyeyenko URS 2= Roma 1987 3 3 2.38 Charles Austin USA 1 Tokyo 1991 3 3 2.38 Mutaz Essa Barshim QAT 2 Moskva 2013 3 3 2.38 Derek Drouin CAN 3 Moskva 2013 Margin of Victory Max 3c m 2.35m Mutaz Essa Barshim QAT London 2017 2.41m Bohdan Bondarenko UKR Moskva 2013 2.40m Javier Sotomayor CUB Stuttgart 1993 2.36m Martin Buss GER Edmonton 2001 2.35m Jacques Freitag RSA Paris 2003 2.32m Yuriy Krimarenko UKR Helsinki 2005 Min 0cm 2. 32m Gennadiy Avd ye yenko URS Helsinki 1983 2.38m Patrik Sjöberg SWE Roma 1987 2.37m Troy Kemp BAH Göteborg 1995 2.35m Donald Thomas BAH Osaka 2007 2.32m Yaroslav Rybakov RUS Berlin 2009 2.35m Jesse Williams USA Daegu 2011 Best Marks for Places in the World Championships Pos Height Name Nat Venue Year 1 2.41 Bohdan Bondarenko UKR Moskva 2013 2.40 Javier Sotomayor CUB Stuttgart 1993 2 2.38 Mutaz Essa Barshim QAT Moskva 2013 Igor Paklin URS Roma 1987 Gennadiy Avdyeyenko URS Roma 1987 3 2.38 Derek Drouin CAN Moskva 2013 2.37 Steve Smith GBR Stuttgart 1993 4 2.36 Dalton Grant GBR Tokyo
    [Show full text]
  • Food Delivery Platform: a Potential Tool for Monitoring the Food Environment and Mitigating Overweight/Obesity in China
    OPINION published: 29 July 2021 doi: 10.3389/fnut.2021.703090 Food Delivery Platform: A Potential Tool for Monitoring the Food Environment and Mitigating Overweight/Obesity in China Na Cong 1, Ai Zhao 2 and Peng Gong 1,3,4* 1 Ministry of Education Key Laboratory for Earth System Modeling, Department of Earth System Science, Tsinghua University, Beijing, China, 2 Vanke School of Public Health, Tsinghua University, Beijing, China, 3 Education Ecological Field Station for East Asian Migratory Birds, Tsinghua University, Beijing, China, 4 Departments of Geography and Earth Sciences, University of Hong Kong, Hong Kong, China Keywords: food delivery platform, food environment monitoring, overweight/obesity, health intervention, China INTRODUCTION A report on the status of nutrition and chronic diseases among Chinese citizens, released on November 23, 2020, revealed that 50.7% of Chinese adults are overweight and obese (1). The rate is Edited by: considerably higher than that in 2002 (29.9%) and 2012 (42%) (2). Overweight and obesity decrease Tong Wu, life expectancy and increase health expenditure (3). According to estimates from the Organization Research Center for for Economic Co-operation and Development (OECD), there is likely to be about 3 years reduced Eco-environmental Sciences life expectancy among the OECD, EU28, and G20 countries, and 92 million people are predicted to (CAS), China die prematurely due to overweight between now and 2050 (3). In addition, 311 billion dollars will Reviewed by: be spent per year (according to the USD Purchasing power parity) treating overweight and related Chaofan Xian, conditions in OECD countries (3). Nonetheless, in 2014, the number of obese people in China rose Chinese Academy of Sciences to first place in the world, and the number of severely obese people has increased to second place (CAS), China globally (4).
    [Show full text]
  • P020110307527551165137.Pdf
    CONTENT 1.MESSAGE FROM DIRECTOR …………………………………………………………………………………………………………………………………………………… 03 2.ORGANIZATION STRUCTURE …………………………………………………………………………………………………………………………………………………… 05 3.HIGHLIGHTS OF ACHIEVEMENTS …………………………………………………………………………………………………………………………………………… 06 Coexistence of Conserve and Research----“The Germplasm Bank of Wild Species ” services biodiversity protection and socio-economic development ………………………………………………………………………………………………………………………………………………… 06 The Structure, Activity and New Drug Pre-Clinical Research of Monoterpene Indole Alkaloids ………………………………………… 09 Anti-Cancer Constituents in the Herb Medicine-Shengma (Cimicifuga L) ……………………………………………………………………………… 10 Floristic Study on the Seed Plants of Yaoshan Mountain in Northeast Yunnan …………………………………………………………………… 11 Higher Fungi Resources and Chemical Composition in Alpine and Sub-alpine Regions in Southwest China ……………………… 12 Research Progress on Natural Tobacco Mosaic Virus (TMV) Inhibitors…………………………………………………………………………………… 13 Predicting Global Change through Reconstruction Research of Paleoclimate………………………………………………………………………… 14 Chemical Composition of a traditional Chinese medicine-Swertia mileensis……………………………………………………………………………… 15 Mountain Ecosystem Research has Made New Progress ………………………………………………………………………………………………………… 16 Plant Cyclic Peptide has Made Important Progress ………………………………………………………………………………………………………………… 17 Progresses in Computational Chemistry Research ………………………………………………………………………………………………………………… 18 New Progress in the Total Synthesis of Natural Products ………………………………………………………………………………………………………
    [Show full text]
  • Chapter 4 China's High-Tech Development
    CHAPTER 4 CHINA’S HIGH-TECH DEVELOPMENT SECTION 1: CHINA’S PURSUIT OF DOMINANCE IN COMPUTING, ROBOTICS, AND BIOTECHNOLOGY Key Findings • China has laid out an ambitious whole-of-government plan to achieve dominance in advanced technology. This state-led ap- proach utilizes government financing and regulations, high market access and investment barriers for foreign firms, over- seas acquisitions and talent recruitment, and, in some cases, industrial espionage to create globally competitive firms. • China’s close integration of civilian and military technology de- velopment raises concerns that technology, expertise, and intel- lectual property shared by U.S. firms with Chinese commercial partners could be transferred to China’s military. • Artificialintelligence: China—led by Baidu—is now on par with the United States in artificial intelligence due in part to robust Chinese government support, establishment of research insti- tutes in the United States, recruitment of U.S.-based talent, investment in U.S. artificial intelligence-related startups and firms, and commercial and academic partnerships. • Quantum information science: China has closed the technolog- ical gap with the United States in quantum information sci- ence—a sector the United States has long dominated—due to a concerted strategy by the Chinese government and inconsistent and unstable levels of R&D funding and limited government coordination by the United States. • High performance computing: Through multilevel government support, China now has the world’s two fastest supercomputers and is on track to surpass the United States in the next gener- ation of supercomputers—exascale computers—with an expect- ed rollout by 2020 compared to the accelerated U.S.
    [Show full text]
  • Childhood Obesity Prevention in China: a Mixed-Methods Approach to Inform Development of Theoretically Based Interventions
    CHILDHOOD OBESITY PREVENTION IN CHINA: A MIXED-METHODS APPROACH TO INFORM DEVELOPMENT OF THEORETICALLY BASED INTERVENTIONS By BAI LI A thesis submitted to the University of Birmingham for the degree of DOCTOR OF PHILOSOPHY Unit of Public Health, Epidemiology and Biostatistics School of Health and Population Sciences College of Medical and Dental Sciences University of Birmingham November 2012 1 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. ABSTRACT Background Childhood obesity is increasing rapidly in China. However, research into environmental contributors to the problem is limited. Formative research that informs theoretically based prevention interventions is also lacking. Aim and objectives To inform the development of obesity prevention interventions among urban Chinese primary school students by: 1. exploring perceived factors contributing to obesogenic behaviours, 2. exploring preferred components and delivery strategies for future preventive interventions, 3. examining the relationship of family and neighbourhood environmental factors, to child weight status as well as related dietary and physical activity behaviours. Methods A mixed-methods study was conducted in two cities in South China. Seventeen focus groups and four personal interviews were conducted with family and primary school members from four socioeconomically distinct districts (objectives 1-2).
    [Show full text]
  • 1. Sars-Cov Nucleocapsid Protein Epitopes and Uses Thereof
    www.engineeringvillage.com Citation results: 500 Downloaded: 4/24/2020 1. SARS-COV NUCLEOCAPSID PROTEIN EPITOPES AND USES THEREOF KELVIN, David; PERSAD, Desmond; CAMERON, Cheryl; BRAY, Kurtis, R.; LOFARO, Lori, R.; JOHNSON, Camille; SEKALY, Rafick-Pierre; YOUNES, Souheil-Antoine; CHONG, Pele Assignee: UNIVERSITY HEALTH NETWORK; BECKMAN COULTER, INC.; UNIVERSITE DE MONTREAL; NATIONAL HEALTH RESEARCH INSTITUTES Publication Number: WO2005103259 Publication date: 11/03/2005 Kind: Patent Application Publication Database: WO Patents Compilation and indexing terms, 2020 LexisNexis Univentio B.V. Data Provider: Engineering Village 2. SARS-CoV-specific B-cell epitope and applications thereof Wu, Han-Chung; Liu, I-Ju; Chiu, Chien-Yu Assignee: National Taiwan University Publication Number: US20060062804 Publication date: 03/23/2006 Kind: Utility Patent Application Database: US Patents Compilation and indexing terms, 2020 LexisNexis Univentio B.V. Data Provider: Engineering Village 3. A RECOMBINANT SARS-COV VACCINE COMPRISING ATTENUATED VACCINIA VIRUS CARRIERS QIN, Chuan; WEI, Qiang; GAO, Hong; TU, Xinming; CHEN, Zhiwei; ZHANG, Linqi; HO, David, D. Assignee: INSTITUTE OF LABORATORY ANIMAL SCIENCE OF CHINESE ACADEMY OF MEDICAL SCIENCES; THE AARON DIAMOND AIDS RESEARCH CENTER; QIN, Chuan; WEI, Qiang; GAO, Hong; TU, Xinming; CHEN, Zhiwei; ZHANG, Linqi; HO, David, D. Publication Number: WO2006079290 Publication date: 08/03/2006 Kind: Patent Application Publication Database: WO Patents Compilation and indexing terms, 2020 LexisNexis Univentio B.V. Data
    [Show full text]
  • Atrocities in China
    ATROCITIES IN CHINA: LIST OF VICTIMS IN THE PERSECUTION OF FALUN GONG IN CHINA Jointly Compiled By World Organization to Investigate the Persecution of Falun Gong PO Box 365506 Hyde Park, MA 02136 Contact: John Jaw - President Tel: 781-710-4515 Fax: 781-862-0833 Web Site: http://www.upholdjustice.org Email: [email protected] Fa Wang Hui Hui – Database system dedicated to collecting information on the persecution of Falun Gong Web Site: http://www.fawanghuihui.org Email: [email protected] April 2004 Preface We have compiled this list of victims who were persecuted for their belief to appeal to the people of the world. We particularly appeal to the international communities and request investigation of this systematic, ongoing, egregious violation of human rights committed by the Government of the People’s Republic of China against Falun Gong. Falun Gong, also called Falun Dafa, is a traditional Chinese spiritual practice that includes exercise and meditation. Its principles are based on the values of truthfulness, compassion, and tolerance. The practice began in China in 1992 and quickly spread throughout China and then beyond. By the end of 1998, by the Chinese government's own estimate, there were 70 - 100 million people in China who had taken up the practice, outnumbering Communist Party member. Despite the fact that it was good for the people and for the stability of the country, former President JIANG Zemin launched in July 1999 an unprecedented persecution of Faun Gong out of fears of losing control. Today the persecution of Falun Gong still continues in China. As of the end of March 2004, 918 Falun Gong practitioners have been confirmed to die from persecution.
    [Show full text]
  • Sex Disparity in the Effect of Obesity in Hospitalized COVID-19 Patients: a Retrospective Cohort Study from the New York City Metropolitan Area
    Open Access Original Article DOI: 10.7759/cureus.15235 Sex Disparity in the Effect of Obesity in Hospitalized COVID-19 Patients: A Retrospective Cohort Study From the New York City Metropolitan Area Ashutossh Naaraayan 1 , Abhishek Nimkar 1 , Sushil Pant 1 , Amrah Hasan 1 , Momcilo Durdevic 1 , Henrik Elenius 1 , Corina Nava Suarez 1 , Stephen Jesmajian 1 1. Internal Medicine, Montefiore New Rochelle Hospital, Albert Einstein College of Medicine, New Rochelle, USA Corresponding author: Ashutossh Naaraayan, [email protected] Abstract Introduction: Obesity has been recognized as a risk factor for poor outcomes in coronavirus disease 2019 (COVID-19) illness. We analyzed the impact of patient characteristics including obesity on hospital mortality and specifically analyzed the effect of obesity by body mass index (BMI) class and by sex. Methods: This retrospective case series included adult patients consecutively hospitalized with confirmed COVID-19 illness between March 12, 2020 and May 13, 2020, at a teaching hospital in the New York City (NYC) metropolitan area. Data were manually extracted from electronic health records by the authors and included demographics, comorbidities, laboratory parameters, and outcomes (hospital mortality or discharge). We used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death. Results: Some 348 patients were included in this study, of whom 207 were discharged and 141 died in the hospital. Multivariable regression showed increasing odds of in-hospital death with older age and excess weight. Interestingly obesity increased mortality in women [odds ratio (OR) 4.4, confidence interval (CI) (1.4-13.5) p=0.01] but not among men [OR 1.4, CI (0.5-3.6) p=0.5].
    [Show full text]
  • Carriera Sotomayor
    1 9 8 3 2.10 1 La Habana 12 Feb (1.90/o - 1.95/o - 2.00/o - 2.05/o - 2.10/o - 2.15/xxx) Alfaro, D.Herrera, Guilarte, P.L.Herrera, Williams, De la Torre, Navarro 2.00 4 La Habana 19 Feb (1.90/o - 1.95/o - 2.00/o - 2.05/xxx) Alfaro, D.Herrera, Diaz / Guilarte, Ruiz, Williams 2.08 3 La Habana 04 Mar (1.90/o - 1.95/o - 2.00/o - 2.05/xo - 2.08/xo - 2.11/xxx) Centelles, Alfaro / D.Herrera, Diaz, Paris, Ruiz 2.08 2 La Habana 08 Mar (1.90/Xo - 1.95/o - 2.00/xo - 2.05/o - 2.08/xxo - 2.11/xxx) Centelles / D.Herrera, Diaz, Guilarte, Williams, Ruiz, Paris. Gutiérrez 2.07 1 Santiago de Cuba 21 Mar (1.90/o - 1.95/o - 2.01/xo - 2.04/xo - 2.07/o - 2.11/xxx) Diaz, Oriol, Prado, Paris, Williams, Scull, Noa, Piedra, Miranda, García 2.00 1 La Habana 02 Apr Diaz, Pinillo, Gutiérrez, Williams, Ibañez, Scull, Valle, Leal, Ibarra 2.10 4 La Habana 18 May (1.90/o - 1.95/o - 2.00/o - 2.05/o - 2.10/o - 2.15/xxx) Centelles, Alfaro, D.Herrera / Ruiz, Acosta, Diaz, Prado, Williams 2.05 7 La Habana 21 May (2.00/o - 2.05/o - 2.10/xxx) Centelles, Alfaro, D.Herrera, Wray, Diaz, Mejias / Prado, Ruiz, Rojas 2.15 2 México, D.F. 16 Jun Risano / Julián 2.02 1 Xochimilco 22 Jun 2.05 1 La Habana 09 Jul D.Herrera, Diaz, P.L.Herrera 2.10 1 La Habana 16 Jul Diaz, D.Herrera, 2.17 3 La Habana 24 Jul Alfaro, Saunders / Glasgow, Vázquez, Williams, Salazar 2.16 3 Leningrad 12 Aug Peev, Sergiyenko / ………5° Gröhler, ……..11° Lüddemann 14 performances 1 9 8 4 2.20 2 San José de Las Lajas 23 Jan (1.95/o - 2.00/o - 2.05/o - 2.10/o - 2.15/o - 2.20/xo - 2.24/xxx) Alfaro / Diaz, D.Herrera, Pinillo,
    [Show full text]
  • Final Program of CCC2020
    第三十九届中国控制会议 The 39th Chinese Control Conference 程序册 Final Program 主办单位 中国自动化学会控制理论专业委员会 中国自动化学会 中国系统工程学会 承办单位 东北大学 CCC2020 Sponsoring Organizations Technical Committee on Control Theory, Chinese Association of Automation Chinese Association of Automation Systems Engineering Society of China Northeastern University, China 2020 年 7 月 27-29 日，中国·沈阳 July 27-29, 2020, Shenyang, China Proceedings of CCC2020 IEEE Catalog Number: CFP2040A -USB ISBN: 978-988-15639-9-6 CCC2020 Copyright and Reprint Permission: This material is permitted for personal use. For any other copying, reprint, republication or redistribution permission, please contact TCCT Secretariat, No. 55 Zhongguancun East Road, Beijing 100190, P. R. China. All rights reserved. Copyright@2020 by TCCT. 目录 (Contents) 目录 (Contents) ................................................................................................................................................... i 欢迎辞 (Welcome Address) ................................................................................................................................1 组织机构 (Conference Committees) ...................................................................................................................4 重要信息 (Important Information) ....................................................................................................................11 口头报告与张贴报告要求 (Instruction for Oral and Poster Presentations) .....................................................12 大会报告 (Plenary Lectures).............................................................................................................................14
    [Show full text]
  • Pharmaceutical Policy in China
    Pharmaceutical policy in China Challenges and opportunities for reform Elias Mossialos, Yanfeng Ge, Jia Hu and Liejun Wang Pharmaceutical policy in China: challenges and opportunities for reform Pharmaceutical policy in China: challenges and opportunities for reform Elias Mossialos, Yanfeng Ge, Jia Hu and Liejun Wang London School of Economics and Political Science and Development Research Center of the State Council of China Keywords DRUG AND NARCOTIC CONTROL PHARMACEUTICAL PREPARATIONS DRUG COSTS DRUG INDUSTRY HEALTH CARE REFORM HEALTH POLICY CHINA © World Health Organization 2016 (acting as the host organization for, and secretariat of, the European Observatory on Health Systems and Policies) All rights reserved. The European Observatory on Health Systems and Policies welcomes requests for permission to reproduce or translate its publications, in part or in full. Address requests about publications to: Publications, WHO Regional Office for Europe, UN City, Marmorvej 51, DK-2100 Copenhagen Ø, Denmark. Alternatively, complete an online request form for documentation, health information, or for permission to quote or translate, on the Regional Office web site (www.euro.who.int/pubrequest). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the European Observatory on Health Systems and Policies concerning the legal status of any country, territory, city or area or of its authorities, or concern- ing the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the European Observatory on Health Systems and Policies in preference to others of a similar nature that are not mentioned.
    [Show full text]